Thomas Fuerst
University of Maryland
H-index: 37
North America-United States
Top articles of Thomas Fuerst
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Site-directed neutralizing antibodies targeting structural sites on SARS-CoV-2 spike protein | New Biotechnology | Xiaofeng Li Liudmila Kulakova Kezzia Jones Eric A Toth Marina Kirkland Mitchell | 2024/5/25 |
Glycoengineered recombinant alpha1-antitrypsin results in comparablein vitroandin vivoactivities to human plasma-derived protein | F Rocamora S Schoffelen J Arnsdorf EA Toth Y Abdul | 2024/3/30 | |
Hepatitis C Virus E1E2 Structure, Diversity, and Implications for Vaccine Development | Brian G Pierce Nathaniel Felbinger Mathew Metcalf Eric A Toth Gilad Ofek | 2024/3/25 | |
Modified secreted hepatitis c virus (hcv) e1e2 glycoproteins and methods of use thereof | 2024/1/18 | ||
Cross-reactive macaque antibodies targeting marburgvirus glycoprotein induced by multivalent immunization | bioRxiv | Benjamin M Janus Ruixue Wang Thomas E Cleveland Matthew C Metcalf Aaron C Lemmer | 2023 |
Glycosylation shapes the efficacy and safety of diverse protein, gene and cell therapies | Frances Rocamora Angelo G Peralta Seunghyeon Shin James Sorrentino Mina Wu | 2023/6/22 | |
Fluorine-Functionalized Polyphosphazene Immunoadjuvant: Synthesis, Solution Behavior and In Vivo Potency | Molecules | Harichandra D Tagad Alexander Marin Ruixue Wang Abdul S Yunus Thomas R Fuerst | 2023/5/21 |
Polyphosphazenes, methods of making, and uses thereof | 2023/4/27 | ||
Polyphosphazene polyelectrolytes and uses thereof | 2023/2/21 | ||
Prospects for developing an Hepatitis C virus E1E2‐based nanoparticle vaccine | Eric A Toth Alexander K Andrianov Thomas R Fuerst | 2023/9 | |
Biographical Feature: Marc S. Collett (23 May 1951–11 June 2022): the Battle against Viral Disease Has Lost a Valiant Warrior, and the World Has Lost a Splendid Human Being | Journal of Virology | Kimberly F Glassman Joan S Brugge Anthony F Purchio Laura T Kakach Thomas R Fuerst | 2023/1/31 |
Structure of engineered hepatitis C virus E1E2 ectodomain in complex with neutralizing antibodies | Nature Communications | Matthew C Metcalf Benjamin M Janus Rui Yin Ruixue Wang Johnathan D Guest | 2023/7/5 |
An antigenically diverse, representative panel of envelope glycoproteins for hepatitis C virus vaccine development | Gastroenterology | Jordan H Salas Richard A Urbanowicz Johnathan D Guest Nicole Frumento Alexis Figueroa | 2022/2/1 |
Skin Vaccination with Ebola Virus Glycoprotein Using a Polyphosphazene-Based Microneedle Patch Protects Mice against Lethal Challenge | Journal of Functional Biomaterials | Andrey Romanyuk Ruixue Wang Alexander Marin Benjamin M Janus Eric I Felner | 2022/12/27 |
Compositions and methods for producing glyco-modified viral antigens | 2022/8/4 | ||
Induction of broadly neutralizing antibodies using a secreted form of the hepatitis C virus E1E2 heterodimer as a vaccine candidate | Proceedings of the National Academy of Sciences | Ruixue Wang Saori Suzuki Johnathan D Guest Brigitte Heller Maricar Almeda | 2022/3/15 |
Modified hepatitis c virus e2 glycoproteins and methods of use thereof | 2022/2/24 | ||
Crystal structure of a bivalent antibody Fab fragment | Journal of Molecular Biology | Salman Shahid Mingming Gao D Travis Gallagher Edwin Pozharski Robert G Brinson | 2021/1/22 |
Structural and biophysical characterization of the HCV E1E2 heterodimer for vaccine development | Open Biology | Evelyn Ploetz Gea Schuurman-Wolters Niels Zijlstra Amarins Jager Douglas A Griffith | 2021 |
Design of a native-like secreted form of the hepatitis C virus E1E2 heterodimer | Proceedings of the National Academy of Sciences | Johnathan D Guest Ruixue Wang Khadija H Elkholy Andrezza Chagas Kinlin L Chao | 2021/1/19 |
